已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer

医学 内科学 乳腺癌 安慰剂 二甲双胍 肿瘤科 癌症 妇科 胰岛素 病理 替代医学
作者
Pamela J. Goodwin,Bingshu E. Chen,Karen A. Gelmon,Timothy J. Whelan,Marguerite Ennis,Julie Lemieux,Jennifer A. Ligibel,Dawn L. Hershman,Ingrid A. Mayer,Timothy J. Hobday,Judith M. Bliss,Priya Rastogi,Manuela Rabaglio,Som D. Mukherjee,John R. Mackey,Vandana G. Abramson,Conrad D. Oja,Robert Wesolowski,Alastair M. Thompson,Daniel Rea
出处
期刊:JAMA [American Medical Association]
卷期号:327 (20): 1963-1963 被引量:148
标识
DOI:10.1001/jama.2022.6147
摘要

Importance

Metformin, a biguanide commonly used to treat type 2 diabetes, has been associated with potential beneficial effects across breast cancer subtypes in observational and preclinical studies.

Objective

To determine whether the administration of adjuvant metformin (vs placebo) to patients with breast cancer without diabetes improves outcomes.

Design, Setting, and Participants

MA.32, a phase 3 randomized, placebo-controlled, double-blind trial, conducted in Canada, Switzerland, US, and UK, enrolled 3649 patients with high-risk nonmetastatic breast cancer receiving standard therapy between August 2010 and March 2013, with follow-up to October 2020.

Interventions

Patients were randomized (stratified for hormone receptor [estrogen receptor and/or progesterone receptor {ER/PgR}] status, positive vs negative; body mass index, ≤30 vs >30; human epidermal growth factor receptor 2 [ERBB2,formerlyHER2orHER2/neu], positive vs negative; and any vs no chemotherapy) to 850 mg of oral metformin twice a day (n = 1824) or oral placebo twice a day (n = 1825) for 5 years.

Main Outcomes and Measures

The primary outcome was invasive disease–free survival in hormone receptor–positive breast cancer. Of the 8 secondary outcomes, overall survival, distant relapse–free survival, and breast cancer–free interval were analyzed.

Results

Of the 3649 randomized patients (mean age, 52.4 years; 3643 women [99.8%]), all (100%) were included in analyses. After a second interim analysis, futility was declared for patients who were ER/PgR−, so the primary analysis was conducted for 2533 patients who were ER/PgR+. The median duration of follow-up in the ER/PgR+ group was 96.2 months (range, 0.2-121 months). Invasive disease–free survival events occurred in 465 patients who were ER/PgR+. The incidence rates for invasive disease–free survival events were 2.78 per 100 patient-years in the metformin group vs 2.74 per 100 patient-years in the placebo group (hazard ratio [HR], 1.01; 95% CI, 0.84-1.21;P = .93), and the incidence rates for death were 1.46 per 100 patient-years in the metformin group vs 1.32 per 100 patient-years in the placebo group (HR, 1.10; 95% CI, 0.86-1.41;P = .47). Among patients who were ER/PgR−, followed up for a median of 94.1 months, incidence of invasive disease–free survival events was 3.58 vs 3.60 per 100 patient-years, respectively (HR, 1.01; 95% CI, 0.79-1.30;P = .92). None of the 3 secondary outcomes analyzed in the ER/PgR+ group had statistically significant differences. Grade 3 nonhematological toxic events occurred more frequently in patients taking metformin than in patients taking placebo (21.5% vs 17.5%, respectively,P = .003). The most common grade 3 or higher adverse events in the metformin vs placebo groups were hypertension (2.4% vs 1.9%), irregular menses (1.5% vs 1.4%), and diarrhea (1.9% vs 7.0%).

Conclusions and Relevance

Among patients with high-risk operable breast cancer without diabetes, the addition of metformin vs placebo to standard breast cancer treatment did not significantly improve invasive disease–free survival.

Trial Registration

ClinicalTrials.gov Identifier: NCT01101438
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
4秒前
长琴思顾发布了新的文献求助10
4秒前
昭荃完成签到 ,获得积分0
4秒前
一直向前发布了新的文献求助10
6秒前
千宝完成签到 ,获得积分10
6秒前
HanruiWang完成签到,获得积分10
8秒前
酷酷问夏完成签到 ,获得积分10
9秒前
毛毛完成签到,获得积分10
9秒前
momo完成签到,获得积分10
9秒前
9秒前
Fn完成签到 ,获得积分10
12秒前
画清风完成签到,获得积分10
13秒前
星辰大海应助伍仨仨采纳,获得10
14秒前
只如初完成签到 ,获得积分10
14秒前
徐zhipei完成签到 ,获得积分10
15秒前
情怀应助科研通管家采纳,获得10
15秒前
Hello应助科研通管家采纳,获得10
15秒前
科研通AI5应助科研通管家采纳,获得30
15秒前
15秒前
Muhammad完成签到,获得积分10
15秒前
Ak完成签到,获得积分0
15秒前
奋斗金连完成签到,获得积分10
17秒前
18秒前
stark完成签到,获得积分10
21秒前
myj完成签到 ,获得积分10
22秒前
甜美宛儿完成签到,获得积分10
24秒前
神外小白发布了新的文献求助10
24秒前
暖暖的禾日完成签到,获得积分10
25秒前
赝品也烂漫完成签到,获得积分10
26秒前
yinlao完成签到,获得积分10
27秒前
Ma完成签到,获得积分10
36秒前
38秒前
斯文败类应助笔墨留香采纳,获得10
38秒前
传奇3应助忐忑的阑香采纳,获得10
40秒前
simon完成签到 ,获得积分10
40秒前
风里有声音完成签到 ,获得积分10
42秒前
王宽宽宽发布了新的文献求助10
43秒前
咪呀完成签到,获得积分10
43秒前
咖啡味椰果完成签到 ,获得积分10
43秒前
ZM完成签到 ,获得积分10
44秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989957
求助须知:如何正确求助?哪些是违规求助? 3532034
关于积分的说明 11255966
捐赠科研通 3270856
什么是DOI,文献DOI怎么找? 1805053
邀请新用户注册赠送积分活动 882252
科研通“疑难数据库(出版商)”最低求助积分说明 809216